(NEW YORK)– International Endeavors Corporation (OTCMKTS: IDVV) released news on their subsidiary partner, KUBBY Cryogenics, Inc., and the positive aspects of their Cryogenic process on adult Brain Stem Cell production.
In a recent release the Company stated, “Our Cryogenic process appears to trigger the production of Adult Stem Cells, based on independent research on the Endocannabinoid system and the entourage effect,” said Steve Kubby, CEO and President of Kubby Cryogenics. According to a recent peer reviewed study, the endocannabinoid system directs cell fate specification of Neural Stem Cells in the Central Nervous System, which can lead to new cell generation in the brain and the periphery systems.
Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process. This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s, and more.
Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use.
Most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.
To accomplish these goals, Kubby Cryogenics has assembled a team of top Scientists and Geneticists to research and develop the strains for these Cryogenic Extract products.
Steven Wynn “Steve” Kubby, the new CEO of IDVV, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Sell the Growers, Buy Medical
The main take away for investors looking to play the marijuana sector is that IDVV isn’t going to be your run of the mill marijuana play, but more in the realm of a ‘biotech research firm’ that conducts its core research on the non-psychoactive use of cannabis using a specialized cryo process.
Ludlow Research, a small cap equity research firm located in New York City, recently issued a note to their subscribers that investors wanting to invest in the marijuana sector may want to sell the growers, dispensaries, and recreational plays, and focus investment capital more in a diversified basket of companies focused strictly on the medical research side due to potential regulatory risks.
For this reason they have initiated coverage on IDVV based on their new management, low public float, and strict focus on non-psychoactive cannabis research for the treatment of a wide variety of illnesses, with a ‘speculative’ short-term target of around $2.00+ per share.
This would place IDVV with similar pure medical marijuana plays such as OWC Pharmaceutical Research Corp (OTC:OWCP) India Globalization Capital, Inc. (NYSE: IGC), Freedom Leaf, Inc. (OTC:FRLF), or Medical Marijuana Inc. (OTC:MJNA) to name just a few.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com